Aurinia Pharmaceuticals Inc. stock rampaged in the extended session, rising more than 110% after the company announced positive efficacy and safety results from a Phase 3 trial for a drug that treats a common complication of lupus, an autoimmune disease. The complication known as lupus nephritis is a frequent complication of the disease commonly known as lupus. “This extraordinary pivotal data confirms voclosporin’s ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care,” Chief Medical Officer Neil Solomons said in a statement. “This data represents a significant advance for people living with LN, which can lead to irreversible kidney damage, eventual kidney failure and death.” The company’s drug is called voclosporin, and Aurinia said it expects that if it achieves regulatory approval then patent protection for the drug will be extended in the U.S. and Europe, among other markets, until 2027. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia and trades on the Toronto Stock Exchange and the Nasdaq. Prior to Wednesday’s after-hours stock move, Aurinia stock had gained 23% this year, as the S&P 500 index also rose 23%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.